Peptide Database

A complex mixture of low-molecular-weight neuropeptides derived from porcine brain proteins. The only peptide-based nootropic with robust clinical evidence for Alzheimer disease and brain injury.

A peptide bioregulator targeting the cerebral cortex and CNS from the Khavinson series. Normalizes cortical neuron function, reduces age-related neurodegeneration, and improves cognitive function. Particularly studied for age-associated cognitive decline, vascular dementia, and post-stroke recovery.

An angiotensin IV-derived peptide that is reportedly millions of times more potent than BDNF at forming functional synaptic connections. Promotes dendritic spine growth via the HGF/c-Met signaling pathway. Researched for Alzheimer's disease, cognitive enhancement, and neuroplasticity.

A neuropeptide that promotes slow-wave (delta wave) sleep and modulates stress hormones. Used for sleep optimization, stress reduction, and recovery enhancement.

The first synthetic drug ever made (1876), now being rediscovered as a potent mitochondrial electron carrier and cognitive enhancer. Acts as an alternative electron acceptor in the mitochondrial electron transport chain, enhancing ATP production and reducing oxidative stress.

A synthetic dipeptide nootropic approximately 1000x more potent than piracetam. Stimulates BDNF and NGF expression with significant neuroprotective and cognitive-enhancing effects.

A synthetic peptide derived from ciliary neurotrophic factor (CNTF) that increases BDNF production, enhances neuroplasticity, and improves cognitive function. Shows promise for Alzheimer's disease, depression, and age-related cognitive decline.

A synthetic heptapeptide derived from the prosegment of sortilin that acts as a selective TREK-1 potassium channel antagonist. Produces rapid antidepressant effects within 4 days — far faster than SSRIs — and demonstrates neuroprotection in stroke and ischemia models.

A synthetic tripeptide (Glu-Asp-Arg) from the Khavinson peptide bioregulator series targeting the brain and pineal gland. Reduces neuronal apoptosis, improves cognitive function in aging models, and normalizes circadian rhythm disruption. Distinct from Epithalon despite also targeting the pineal gland.

A synthetic heptapeptide derived from tuftsin that exhibits anxiolytic, nootropic, and immunomodulatory effects. Considered a milder anxiolytic counterpart to Semax with a strong safety profile.

An enhanced form of Selank with N-acetyl and C-terminal amide modifications that increase potency and stability. Approximately 2x more potent than standard Selank with longer duration of action.

A synthetic heptapeptide derived from ACTH 4-7 that significantly boosts BDNF levels. Widely used in Russia for cognitive enhancement, stroke recovery, and neurological conditions.

A modified form of Semax with both N-terminal acetylation and C-terminal amidation, making it 2-3x more potent than standard Semax and more resistant to enzymatic degradation. The preferred form for cognitive enhancement due to its improved bioavailability and stability.